Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Identifieur interne : 001E28 ( Main/Corpus ); précédent : 001E27; suivant : 001E29Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Auteurs : C. Pritchard ; K. NadarajahSource :
- Annals of the rheumatic diseases [ 0003-4967 ] ; 2004.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antibodies, Monoclonal.
- drug therapy : Sarcoidosis.
- Adult, Aged, Chronic Disease, Female, Humans, Infliximab, Male, Treatment Outcome.
Abstract
OBJECTIVE
To study the effectiveness of tumour necrosis factor alpha (TNFalpha) inhibitor treatment for sarcoidosis refractory to conventional treatments.
METHODS
Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4-8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test.
RESULTS
Sarcoidosis in all patients improved significantly without any serious adverse reactions.
CONCLUSION
This study suggests that TNFalpha is effective in patients for whom conventional treatment fails.
DOI: 10.1136/ard.2002.004226
PubMed: 14962969
PubMed Central: PMC1754920
Links to Exploration step
pubmed:14962969Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.</title><author><name sortKey="Pritchard, C" sort="Pritchard, C" uniqKey="Pritchard C" first="C" last="Pritchard">C. Pritchard</name><affiliation><nlm:affiliation>Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nadarajah, K" sort="Nadarajah, K" uniqKey="Nadarajah K" first="K" last="Nadarajah">K. Nadarajah</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:14962969</idno><idno type="pmid">14962969</idno><idno type="pmc">PMC1754920</idno><idno type="doi">10.1136/ard.2002.004226</idno><idno type="wicri:Area/Main/Corpus">001E28</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001E28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.</title><author><name sortKey="Pritchard, C" sort="Pritchard, C" uniqKey="Pritchard C" first="C" last="Pritchard">C. Pritchard</name><affiliation><nlm:affiliation>Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nadarajah, K" sort="Nadarajah, K" uniqKey="Nadarajah K" first="K" last="Nadarajah">K. Nadarajah</name></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="ISSN">0003-4967</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Chronic Disease (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Infliximab (MeSH)</term><term>Male (MeSH)</term><term>Sarcoidosis (drug therapy)</term><term>Treatment Outcome (MeSH)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Sarcoidosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Chronic Disease</term><term>Female</term><term>Humans</term><term>Infliximab</term><term>Male</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To study the effectiveness of tumour necrosis factor alpha (TNFalpha) inhibitor treatment for sarcoidosis refractory to conventional treatments.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4-8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sarcoidosis in all patients improved significantly without any serious adverse reactions.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>This study suggests that TNFalpha is effective in patients for whom conventional treatment fails.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14962969</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4967</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.</ArticleTitle><Pagination><MedlinePgn>318-20</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To study the effectiveness of tumour necrosis factor alpha (TNFalpha) inhibitor treatment for sarcoidosis refractory to conventional treatments.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Five patients (two men, three women) were treated with infliximab. All patients received a loading dose of 3 mg/kg at 0, 2, and 6 weeks and then maintenance infusions every 4-8 weeks. Patients had their dose increased or the dosing interval reduced when the disease relapsed. These patients had active disease despite treatment with corticosteroids and other immunomodulatory agents. All patients had a negative tuberculin skin test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sarcoidosis in all patients improved significantly without any serious adverse reactions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study suggests that TNFalpha is effective in patients for whom conventional treatment fails.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pritchard</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Specialty Center, 2400 Maryland Road, Suite 40, Willow Grove, PA 19090, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nadarajah</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>14</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14962969</ArticleId><ArticleId IdType="pmc">PMC1754920</ArticleId><ArticleId IdType="doi">10.1136/ard.2002.004226</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/WillowV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001E28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= WillowV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:14962969
|texte= Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:14962969" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a WillowV1
| This area was generated with Dilib version V0.6.37. |  |